Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Bristol Myers Squibb has received a consensus rating of "Hold" from 21 rated firms, with 15 analysts recommending a hold, 5 a buy, and 1 a strong buy.
• The company reported earnings of $1.46 EPS for the last quarter, exceeding estimates significantly, with revenues of $12.27 billion.
• Bristol Myers Squibb announced a quarterly dividend of $0.62 per share, reflecting an annualized yield of 5.6%, with a payout ratio of 100%.

Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) has received a consensus recommendation of "Hold" from the twenty-one ratings firms that are presently covering the company, MarketBeat reports. Fifteen equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $57.1429.

A number of analysts have recently commented on the company. Daiwa America cut Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Dbs Bank upgraded Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. Daiwa Capital Markets cut Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Saturday, September 27th.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.09% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors have recently added to or reduced their stakes in the business. Beacon Investment Advisory Services Inc. boosted its holdings in Bristol Myers Squibb by 2.7% in the 1st quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock valued at $492,000 after purchasing an additional 212 shares in the last quarter. Exchange Capital Management Inc. boosted its holdings in Bristol Myers Squibb by 0.4% in the 2nd quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company's stock valued at $2,541,000 after purchasing an additional 220 shares in the last quarter. 1858 Wealth Management LLC boosted its holdings in Bristol Myers Squibb by 3.6% in the 1st quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock valued at $392,000 after purchasing an additional 221 shares in the last quarter. Parsons Capital Management Inc. RI boosted its holdings in Bristol Myers Squibb by 0.3% in the 2nd quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company's stock valued at $3,615,000 after purchasing an additional 224 shares in the last quarter. Finally, Richwood Investment Advisors LLC boosted its holdings in Bristol Myers Squibb by 1.7% in the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company's stock valued at $616,000 after purchasing an additional 225 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 0.2%

BMY opened at $44.65 on Friday. The business's 50-day simple moving average is $46.27 and its 200-day simple moving average is $48.22. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb has a one year low of $42.96 and a one year high of $63.33. The stock has a market capitalization of $90.88 billion, a P/E ratio of 18.00, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the previous year, the firm earned $2.07 earnings per share. The business's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts anticipate that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.6%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb's payout ratio is 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.